Replimune Group (NASDAQ:REPL) Shares Down 4.2% – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL) shares traded down 4.2% on Monday . The company traded as low as $14.14 and last traded at $14.30. 134,294 shares were traded during trading, a decline of 87% from the average session volume of 1,050,196 shares. The stock had previously closed at $14.93.

Wall Street Analysts Forecast Growth

REPL has been the topic of several research analyst reports. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Roth Mkm assumed coverage on Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research note on Friday. JPMorgan Chase & Co. upped their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Finally, BMO Capital Markets raised their price objective on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $17.00.

Replimune Group Price Performance

The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The firm has a 50 day moving average of $11.59 and a two-hundred day moving average of $9.76. The company has a market cap of $907.25 million, a PE ratio of -4.35 and a beta of 1.19.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07. Research analysts predict that Replimune Group, Inc. will post -3.02 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of REPL. Barclays PLC increased its position in shares of Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after purchasing an additional 98,791 shares during the last quarter. Geode Capital Management LLC increased its holdings in Replimune Group by 17.9% during the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after buying an additional 217,308 shares during the last quarter. State Street Corp raised its position in Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after acquiring an additional 1,182,181 shares during the period. Parkman Healthcare Partners LLC boosted its stake in shares of Replimune Group by 45.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock worth $8,371,000 after acquiring an additional 238,747 shares during the last quarter. Finally, Arizona PSPRS Trust bought a new stake in shares of Replimune Group during the 3rd quarter valued at $834,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.